Daprodustat

达普司他

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameDaprodustat
Drug Alias Name达度司他Daprodustatum达普司他Duvroqダーブロック +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHypoxia-inducible factor prolyl hydroxylase inhibitorsErythropoiesis stimulants
TargetsHypoxia-inducible factor prolyl hydroxylase
Therapy Area/IndicationsTendon InjuriesWounds and InjuriesAnemia +[6] 
Global Approved IndicationsAnemia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2020/06/29
Country/TerritoryCzechiaBelgiumBulgaria +[44] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Bocimed Pharmaceutical Co LtdGlaxosmithkline PlcQilu Pharmaceutical(Hainan) Co Ltd +[6] 
Inactive CompaniesN/A
Active IndicationsAnemia
Inactive IndicationsTendon InjuriesWounds and InjuriesPeripheral Vascular Diseases +[5] 

Other Information

ATC CodeN/A
Related LinksN/A